In 2015, there were 10.4 million cases of active tuberculosis (TB) and 1.4 million deaths due to TB. While we have effective TB treatment, the incidence of drug resistant cases is increasing and threatens TB control efforts. In 2015, 480,000 new cases of multi drug-resistant TB (MDR-TB) were reported. Among these, nearly 60,000 were extensively drug-resistant TB (XDR-TB). The scenario is much worse in some regions. In Belarus, close to one of each two cases (48%) are MDR-TB (35.3% in new and 76.5% in previously treated TB-patients). Since the global cure rate of MDR-TB is still well below the target set by WHO for 2015 (exceedingly low in many parts of the world), and since XDR-TB treatment success rates are even lower (20% in Belarus), there is an urgent need for improved understanding of the problem and to identify/evaluate new drugs/combinations of drugs as the situation in Belarus is likely to spread. Two trials for combinatorial treatment involving four new and repurposed drugs bedaquiline, linezolid, clofazimine, and delamanid are underway thanks to funding from the World Health Organization and the Global Fund. As part of these two trials, monthly sputum samples will be collected for six months from all patients. Unfortunately, in the first trial with 30 patients having completed the combinatorial treatment, in six the treatment has failed, and one death has been recorded. This project aims to leverage the resources created by the two trials in order to uncover previously unknown mechanisms of drug resistance, evolutionary path to resistance, and timeline to resistance to the four new/repurposed drugs. Our approach will be to use in silico comparative genomic and epigenetic (methylome and transcriptomic) analysis in order to curate a comprehensive catalog of uncharacterized (epi)genomic changes in failed treatment cases. In silico functional characterization of genes and regulatory elements associated with resistance to the five study drugs will then elucidate the mechanism of resistance. A subsequent phylogenomic analysis and MIC characterization of time-course samples will allow us to understand the evolutionary path to resistance, and the change in resistance level after each evolutionary event. This will allow us to understand for example whether resistance emerges in steps with increasing levels, or spontaneously at a high level. In the case of the former, we will be able to identify the stepwise genetic and methylation markers associated with each resistance level. This allows the clinician to decide whether increasing the drug dosage or change of the drug regimen is the best course of action.

Public Health Relevance

Tuberculosis (TB) is now the most deadly infectious disease that is contracted by more than 10 million people and causes nearly 1.5 mission deaths annually. Emergence of drug resistance is a major problem in global TB control. Already we have observed several cases of failed treatment and one death in trials introducing four new/repurposed anti-TB drugs. This project aims to identify mechanisms of resistance to these new drugs and to provide early markers for the emerging resistance before its establishment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI105185-05A1
Application #
9449175
Study Section
Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section (DDR)
Program Officer
Lacourciere, Karen A
Project Start
2013-07-19
Project End
2022-06-30
Budget Start
2018-07-17
Budget End
2019-06-30
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost
Name
San Diego State University
Department
Biostatistics & Other Math Sci
Type
Schools of Arts and Sciences
DUNS #
073371346
City
San Diego
State
CA
Country
United States
Zip Code
92182
Marney, Matthew W; Metzger, Robert P; Hecht, David et al. (2018) Modeling the structural origins of drug resistance to isoniazid via key mutations in Mycobacterium tuberculosis catalase-peroxidase, KatG. Tuberculosis (Edinb) 108:155-162
Elghraoui, Afif; Modlin, Samuel J; Valafar, Faramarz (2017) SMRT genome assembly corrects reference errors, resolving the genetic basis of virulence in Mycobacterium tuberculosis. BMC Genomics 18:302
Ramirez-Busby, S M; Rodwell, T C; Fink, L et al. (2017) A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis. Sci Rep 7:3790
Berrada, Zenda L; Lin, Shou-Yean Grace; Rodwell, Timothy C et al. (2016) Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex. Diagn Microbiol Infect Dis 85:177-81
Valafar, Faramarz (2016) Pathogenesis of multi drug-resistant and extensively drug-resistant tuberculosis as a determinant of future treatment success. Int J Mycobacteriol 5 Suppl 1:S64-S65
Colman, Rebecca E; Anderson, Julia; Lemmer, Darrin et al. (2016) Rapid Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study. J Clin Microbiol 54:2058-67
Georghiou, S B; Seifert, M; Catanzaro, D et al. (2016) Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape. Antimicrob Agents Chemother 60:3994-4004
ElMaraachli, W; Slater, M; Berrada, Z L et al. (2015) Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations. Int J Tuberc Lung Dis 19:1222-6
Ramirez-Busby, Sarah M; Valafar, Faramarz (2015) Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 59:5267-77
Torres, Jessica N; Paul, Lynthia V; Rodwell, Timothy C et al. (2015) Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates. Emerg Microbes Infect 4:e42

Showing the most recent 10 out of 18 publications